Homeless Health Care Los Angeles, Los Angeles, CA, United States of America.
University of California, Riverside School of Medicine, United States of America.
J Subst Abuse Treat. 2021 Feb;121:108181. doi: 10.1016/j.jsat.2020.108181. Epub 2020 Oct 21.
Syringe exchange patients in Los Angeles' Skid Row endure conditions such as deep poverty, polysubstance use, underlying health problems, and living on the streets or in homeless encampments/shelters that make them uniquely vulnerable to acquiring and dying from COVID-19. In this commentary, we discuss two essential changes that Homeless Health Care Los Angeles (HHCLA) made to modify existing medication for addiction treatment (MAT) services to address the specific treatment needs of this high-risk population during COVID-19. First, HHCLA implemented a novel "telephone booth" model that allowed socially distanced on-site "face-to-face" treatment of syringe exchange patients; this model helped us to overcome the inherent challenges of using traditional telemedicine approaches (e.g., video, mobile telephone) with this disadvantaged patient population. Second, HHCLA transitioned from on-site direct dispensing of MAT medications in our providers' offices to a less contact- and time-intensive "coordinated pharmacy" model that allowed patients the freedom to obtain MAT medications off-site from participating pharmacies. Our data indicate that implementing these COVID-19-related changes effectively maintained patient enrollment and engagement in MAT-illuminating new, potentially effective models for delivering MAT that meet the critical health and safety needs of syringe exchange patients following COVID-19.
洛杉矶“贫民区”的注射毒品者交换项目患者生活在极度贫困、多种药物滥用、潜在健康问题以及街头或无家可归者营地/收容所中,这些情况使他们极易感染和死于 COVID-19。在这篇评论中,我们讨论了洛杉矶无家可归者医疗保健组织(HHCLA)为解决 COVID-19 期间这一高危人群的特定治疗需求而对现有的成瘾治疗药物(MAT)服务进行的两项重要改变。首先,HHCLA 实施了一种新颖的“电话亭”模式,允许在现场进行社会隔离的“面对面”治疗注射毒品者;这种模式帮助我们克服了使用传统远程医疗方法(例如视频、移动电话)为这一弱势群体提供治疗的固有挑战。其次,HHCLA 将 MAT 药物的现场直接配药从我们提供者的办公室过渡到接触和时间密集程度较低的“协调药房”模式,使患者能够自由地从参与的药房获得 MAT 药物。我们的数据表明,实施这些与 COVID-19 相关的改变有效地维持了患者对 MAT 的参与和登记,为满足 COVID-19 后注射毒品者的关键健康和安全需求提供了新的、潜在有效的 MAT 交付模式。